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This article will review myogenic cell transplantation for congenital and acquired diseases
of skeletal muscle. There are already a number of excellent reviews on this topic, but
they are mostly focused on a specific disease, muscular dystrophies and in particular
Duchenne Muscular Dystrophy. There are also recent reviews on cell transplantation for
inflammatory myopathies, volumetric muscle loss (VML) (this usually with biomaterials),
sarcopenia and sphincter incontinence, mainly urinary but also fecal. We believe it would
be useful at this stage, to compare the same strategy as adopted in all these different
diseases, in order to outline similarities and differences in cell source, pre-clinical models,
administration route, and outcome measures. This in turn may help to understand
which common or disease-specific problems have so far limited clinical success of
cell transplantation in this area, especially when compared to other fields, such as
epithelial cell transplantation. We also hope that this may be useful to people outside
the field to get a comprehensive view in a single review. As for any cell transplantation
procedure, the choice between autologous and heterologous cells is dictated by a
number of criteria, such as cell availability, possibility of in vitro expansion to reach the
number required, need for genetic correction for many but not necessarily all muscular
dystrophies, and immune reaction, mainly to a heterologous, even if HLA-matched
cells and, to a minor extent, to the therapeutic gene product, a possible antigen for
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the patient. Finally, induced pluripotent stem cell derivatives, that have entered clinical
experimentation for other diseases, may in the future offer a bank of immune-privileged
cells, available for all patients and after a genetic correction for muscular dystrophies
and other myopathies.
Keywords: cell transplantation, muscle stem cells, muscular dystrophies, mitochondrial myopathies,
inflammatory myopathies, sphincter incontinence, volumetric muscle loss
INTRODUCTION
Cell and stem cell therapies have been in the clinics for more
than a century, starting with blood transfusion, bone marrow
transplantation, and epidermal transplantation for large burns.
They have saved millions of lives and all are consolidated
therapies, since a time when the concept of stem cells did not
exist, at least in its modern meaning (Cossu et al., 2018).
However, it was the explosion of stem cell biology around
the beginning of this century that fueled work into clinical
translation, with premature enthusiasm based on the unproven
assumption that they would be a magical tool to heal virtually
any yet untreatable disease. Instead, recent history of stem
cell therapy has taught us several lessons and provided us
with evidence that could have been predicted. Unfortunately,
the enthusiasm for this new therapeutic avenue and the
pressure from patients, in a long and often desperate wait for
a lifesaving or life-changing therapy, forced research toward
clinical experimentation. It is, however true that, although pre-
clinical work in small and large animal models is indispensable
to predict the possible efficacy of a given experimental strategy,
the final and definitive answer is only provided by clinical trials;
therefore, a difficult equilibrium has to be found between the need
to accumulate sufficient evidence and the risk of delaying trials
that may be successful.
We know now that stem cells have produced dramatic clinical
results only in diseases affecting epithelia, such as epidermis and
cornea, and hematopoietic tissues. This is due to several reasons
including the constant self-renewal that only occurs in these
tissues, their unique physical nature (a liquid suspension or a
bi-dimensional sheet) but the most relevant is the possibility of
ablating the majority or the totality, for epithelia, of diseased cells
so that engraftment of donor cells may easily attain 80–100%
of the cells, virtually replacing the large majority of the resident
tissue cell population (Cossu et al., 2018). For comparison, intra-
arterial transplantation of donor mesoangioblasts in patients
with Duchenne muscular dystrophy (DMD) resulted in 0.7%
of engraftment in the muscles of the youngest patient, clearly
insufficient to detect any clinical benefit, even though donor
derived dystrophin was clearly detected (Cossu et al., 2015). In
reality other genetic diseases have been successfully treated, such
as lysosomal storage diseases, but also in this case the strategy
has relied upon the transplantation of HSC genetically corrected
to over-express the product of the mutated gene in HSC-derived
phagocytes (Staal et al., 2019).
While the advantage of life-long self-renewing stem cells
is obvious for the above-mentioned tissues, skeletal muscles
are believed to renew only a few times in a life-time under
physiological conditions and adjust to increasing demand by
hypertrophy rather than by hyperplasia. Maybe this is at least
one reason why there are stem/progenitor cells in skeletal muscle
with a limited self-renewal capacity, at least when compared with
HSC (Rocheteau et al., 2012). The biology of muscle stem cells
is now a heavily investigated field, though mainly in rodents, but
also increasingly in human cells (Marg et al., 2014, 2019; Snijders
et al., 2015); moreover, in muscle diseases with continuous cycles
of degeneration/regeneration, such as DMD, regeneration after
a while essentially ceases due to the exhaustion of the resident
muscle stem cells/satellite cells and the tissue is progressively
replaced by fat and connective tissue (Lu et al., 2014). It has also
been shown that fibro-adipogenic progenitors play a complex role
in regeneration by promoting satellite cell activation even if their
fate is to produce fat and fibrotic scar tissue (Joe et al., 2010). In
general, dealing with fibrosis is crucial for any specific therapeutic
strategy. Whichever the case, one lesson learned from many other
genetic diseases is that intervention must be as precocious as
possible or hope of efficacy will essentially vanish.
In this review we will start with a brief history of
cell transplantation for diseases of skeletal muscle, followed
by a description of different types of progenitor cells for
transplantation. These include several “non-myogenic” cell types,
such as mesenchymal stromal (often referred as “stem”) cells
or hematopoietic stem cells, based on the fact that these
cells produce growth factors and cytokines thus eliciting some
paracrine beneficial effect. Recent history of cell transplantation
for heart diseases, not to be reviewed here, has clearly shown that
a paracrine effect alone is not sufficient to guarantee significant
and long-lasting clinical efficacy.
We then will examine in detail cell transplantation for
DMD, other forms of muscular dystrophies and mitochondrial
myopathies, inclusion body myositis, sphincter incontinence,
sarcopenia, cachexia and volumetric muscle loss (VML)
(Figure 1). By comparing these different muscle diseases,
we aim to learn common rules and peculiarities, reasons
for failure or incomplete success and set the basis for a new
phase of cell therapy which will also capitalize from the
impressive new knowledge recently acquired on satellite and
other myogenic cells.
BRIEF HISTORY OF CELL THERAPY FOR
MUSCLE
The pioneering work of Partridge et al. (1989) performed in
mdx mouse model for DMD confirmed the ability of injected
myoblasts to colonize striated muscle and restore function. This
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FIGURE 1 | A simplified scheme of the different cell types (only few examples are shown) available for transplantation in different muscle disorders.
stimulated the use of allogeneic myoblasts in clinical trials to
restore muscle function in DMD (Huard et al., 1992; Karpati
et al., 1993; Tremblay et al., 1993; Mendell et al., 1995). These
first trials were followed by other pilot investigations in DMD or
Becker muscular dystrophy (BMD) (Gussoni et al., 1997; Miller
et al., 1997; Neumeyer et al., 1998). These pioneering studies
unfortunately resulted in limited or no clinical effect, mostly
because of immunological incompatibility and massive death of
transplanted cells, which led to a diffuse skepticism that this
strategy may work in the future. However, they established the
feasibility of cell therapy in human skeletal muscle and revealed
many bottlenecks that were totally unexpected. Many questions
were raised and discussed within the scientific community
following these early trials, such as local vs. systemic delivery,
allografts vs. autologous transfer (and the necessity to correct the
implanted cells), the state of the target muscle(s) and the impact
of fibrosis, among many others (Negroni et al., 2016). Since then,
and in response to these debates, several stem cell candidates
with a myogenic potential have been tested, either in animal
models, or more rarely (such as mesoangioblasts or CD133 cells)
in clinical trials. The rationale behind this was directly derived
from the experience gained in the field of gene therapy for
congenital immune deficiencies. As long as lymphocytes were
genetically corrected, the clinical benefit remained linked to
the survival of transduced cells, whereas when long-term self-
renewing stem cells were transduced, the clinical benefit appeared
to be long-lasting, as genetically corrected lymphocytes were
continuously produced and there is today a thirty-year follow up
of the first treated patients none of whom has had any relapse
of the original disease (Ferrua and Aiuti, 2017). As mentioned
above, the characterization of muscle stem/progenitor cells is
still ongoing; however, several trials with satellite cells and other
progenitors have been carried out and are described in the
following paragraphs.
In general, cell therapy to treat muscular dystrophies has been
based on a trial-and-error strategy, and while very few recent
trials have shown some clinical benefit, each trial has brought a
significant load of information that is instrumental to increase
future chances of success.
DIFFERENT TYPES OF PROGENITOR
CELLS FOR TRANSPLANTATION
Ideally, progenitors for muscle cell therapy should be endowed
with the following properties: (1) high muscle regenerative
capacity upon delivery; (2) contribution to the muscle stem
cell pool, essential for long-term homeostasis; (3) ability to
maintain regenerative properties upon in vitro culture, which
is necessary for expansion from a small biopsy; (4) amenability
for genome engineering; (5) extravasation potential following
systemic delivery (for widespread muscle diseases); (6) muscle
tropism following delivery, such as few/no cells will be retained
by the liver, lung or other organs; (7) elicit low to no immune
response, which is particularly relevant for sustained expression
of the therapeutic gene over a long period of time; (8) simple
and robust manufacturing. Over the past three decades, many
studies have attempted to identify cell populations that could
be effectively used to promote skeletal muscle repair in a
clinical setting (reviewed in Martin et al., 2019; Ortiz-Vitali
and Darabi, 2019; Biressi et al., 2020; Łoboda and Dulak, 2020;
Sun et al., 2020). Here we provide a brief overview of these
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efforts and discuss novel technologies that could improve or
complement future cell-based interventions. Table 1 shows a
synthetic overview of the different cell types.
Satellite Cells
Skeletal muscle homeostasis is ensured by a tissue-resident stem
cell population referred as satellite cells. These cells are located
beneath the sarcolemma and express the transcription factor
Pax7 (Mauro, 1961; Seale et al., 2000). In adult healthy muscle,
satellite cells are in a quiescent state, characterized by low
transcriptional and metabolic activities. In response to various
cues, these cells quickly exit quiescence, increase their cellular
activities and generate a population of transient amplifying
progenitors, referred as myoblasts or myogenic progenitor cells,
which ultimately fuse to and repair the damaged myofibers
(Scharner and Zammit, 2011). Importantly, each activation cycle
is also associated with the replenishment of the muscle stem cell
pool, which involves the concerted action of several effectors
controlling symmetric and asymmetric satellite cell division
(Feige et al., 2018). Various studies have demonstrated that
satellite cells are endowed with a high regenerative capacity
upon intramuscular injection in murine models. While this
property makes satellite cells the obvious candidate population
for cell therapy, their clinical use is still problematic. In fact,
satellite cells quickly lose their regenerative potential following
in vitro culture (Montarras et al., 2005; Sacco et al., 2008),
thus implying the requirement of a substantial amount of
donor muscle tissue to obtain sufficient numbers of these
progenitors for downstream applications. Furthermore, satellite
cells show no muscle homing ability upon systemic delivery
(Choi et al., 2020), which represents a significant limitation for
the treatment of pathologies affecting multiple muscle types.
Efforts over the past few years have identified critical aspects
regulating satellite cell maintenance and quiescence: substrate
rigidity, niche components, signaling pathways, and many more
(reviewed in Feige et al., 2018). An increasing number of reports
are now focusing on the characterization of human satellite
cells, which can be prospectively isolated using various surface
markers (CD56, CD82, β1-Integrin, EGFR) (Charville et al.,
2015; Alexander et al., 2016; Uezumi et al., 2016). Combined to
advanced culture systems, these ongoing studies may enable the
effective therapeutic application of human satellite cells to treat
skeletal muscle degenerative disorders.
Myoblasts
Myoblasts constitute the committed derivative of satellite cells,
which ultimately fuse to and, if necessary, repair the myofiber
(Forcina et al., 2020). At the molecular level, myoblasts are
defined by the expression of the muscle regulatory factors
(MRFs) Myf5 and MyoD, which are induced following satellite
cell activation (Buckingham and Rigby, 2014). Myoblast-
mediated muscle repair involves cell cycle exit and differentiation
into myocytes, processes controlled at the molecular level
by two distinct MRFs: Myogenin and Myf6. As myoblasts
transit into myocytes, additional key steps are required for
myofiber formation, including cell fusion and sarcomere
formation, among others (Buckingham and Rigby, 2014;
Petrany and Millay, 2019). Although myoblasts display lower
regenerative potential compared to satellite cells and limited
migration from the injection site, there are advantages, such as
easy collection and expansion. Accordingly, myoblast cultures,
defined as CD56+ cells, are established by digesting muscle
biopsies followed by in vitro expansion (Blau and Webster,
1981). Several methods to enrich for “stem cell-like” myogenic
progenitors have been reported (Deasy et al., 2001; Hashimoto
et al., 2004; Alonso-Martin et al., 2016; Maesner et al., 2016; Hicks
et al., 2018). For example, myoblasts, expanded after a period of
hypothermia without enzymatic digest give rise to pure myogenic
cell populations with high regenerative capacity that repopulate
the stem cell niche (Marg et al., 2014). Injection of myoblasts in
non-human primate models provided important preclinical data
about host-mediated immune rejection, immunosuppression
regimen, number of injections, delivery system, and migration
from the injection site (Skuk et al., 2011, 2014; Skuk and
Tremblay, 2012, 2017, 2020).
Side Population and Interstitial Muscle
Cells
Additional myogenic cell populations have been identified in
the skeletal muscle, including side population cells, PW1+ cells
and TWIST2+ cells. Originally identified in the hematopoietic
system, side population cells express the ABCG2 transporter,
which accounts for the dye-exclusion properties exhibited by
these cells (Gussoni et al., 1999). Side population cells have been
reported to home to skeletal muscles upon systemic delivery
but, unfortunately, possess limited regenerative properties
(Muskiewicz et al., 2005). PW1+ and TWIST2+ cells are
myogenic cells located within the muscle interstitium. PW1+
cells are endowed with in vitro and in vivo myogenic potential
and can contribute to the satellite cell pool (Mitchell et al., 2010).
TWIST2+ cells contribute mainly to type IIb/x fibers in vivo,
and genetic ablation of these cells results in wasting of type IIb
myofibers (Liu et al., 2017).
Mesoangioblasts (MABs)
These progenitors, initially identified in the dorsal aorta of
developing embryos (Minasi et al., 2002), are also present in
post-natal skeletal muscle as a vessel-associated cell population.
MABs have similar properties to and likely represent the
in vitro derivative of adult pericytes (Dellavalle et al., 2007);
they are capable of differentiating into several mesodermal
lineages when derived from embryonic tissues, including skeletal
and cardiac muscle, bone, and cartilage (Cossu and Bianco,
2003). Human skeletal muscle derived MABs are defined by
the expression of the pericyte markers NG2 proteoglycan and
alkaline phosphatase (ALP) and absence of endothelial markers.
This enabled their prospective isolation from freshly dissociated
ALP+ cells (Dellavalle et al., 2007). Their differentiation potency
is restricted to skeletal and smooth muscle in vitro and in vivo
(Dellavalle et al., 2011). Importantly, MABs can be genetically
manipulated in vitro and, following intra-arterial injection, they
efficiently home to skeletal muscle, contributing to regeneration
in both murine and canine DMD models (Sampaolesi et al.,
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TABLE 1 | A simplified scheme of most common cell types used for transplantation, with features, limitations and current use in trials.
Cell type Main features Limitations Tested in clinical trials
Satellite cells • Endogenous stem cell population that
contributes to long term muscle homeostasis
• Single cell transplantation studies evidenced a
high regenerative capacity
• Stem cell properties are not preserved upon
in vitro culture
• Isolation of a therapeutically relevant number of
satellite cells requires a substantial amount of
muscle tissue
No
Myoblasts • Easy isolation and manufacturing following a
small muscle biopsy
• Banking may allow use of HLA-matched
preparations
• May be genetically corrected
• Large numbers are required for extensive
muscle regeneration
• Low survival post-injection
Yes
Mesoangioblasts • Easy isolation and manufacturing following a
small muscle biopsy
• Muscle homing upon intra-arterial systemic
delivery
• Myogenic potential is preserved during in vitro
expansion and genetic manipulation.
• Large numbers are required for extensive
muscle regeneration
• Myogenic potency lower than in myoblasts.
Yes
Muscle interstitial populations • Side population cells are endowed with muscle
homing potential
• TWIST2+ cells display fiber type selectivity
• Autologous transplantation requires muscle
tissue biopsy
• Undefined muscle regenerative potential
• Undefined cell manufacturing process
No
Mesenchymal stromal cells • Established isolation process
• Potential immunomodulatory function
• Conflicting data in terms of in vivo muscle
regenerative potential
Yes
CD133+ cells • Easy isolation and manufacturing following a
small muscle biopsy
• Muscle homing upon systemic delivery
• Myogenic potential is preserved during in vitro
expansion and genetic manipulation
• Large numbers required for extensive muscle
regeneration are difficult to be reached.
Yes
iPSC-derived myogenic progenitors • Amenable to genome editing prior to
specification of the myogenic lineage
• Banking may allow use of HLA-matched
preparations
• Maybe genetically corrected
• Myogenic potential is preserved during in vitro
expansion
• Muscle homing upon systemic delivery
(demonstrated for murine cells)
• Large numbers are required for extensive
muscle regeneration
• Potential risk of teratogenicity if residual
pluripotent stem cells are present in the
myogenic cell preparation
No
2003, 2006; Tedesco et al., 2011). Analysis of MAB-transplanted
muscles showed that these cells also contribute, though to a
limited extent, to the satellite cell pool, which represents an
important aspect for ensuring long-term muscle homeostasis
(Tedesco et al., 2011). Lastly, in vitro studies demonstrated that
human MABs can also act as immunomodulatory cells, through
an Indoleamine 2,3-dioxygenase (IDO) and prostaglandin
E-2 (PGE)-mediated suppression of T cell proliferation
(English et al., 2013).
Bone Marrow Derived-Hematopoietic
Stem Cells and CD133+ Cells
Cells endowed with myogenic potential have also been identified
in the hematopoietic system (Ferrari et al., 1998). While bone
marrow transplantation showed inefficient muscle regeneration
(Ferrari et al., 2001), promising results were obtained using
circulating CD133+ cells, also defined as CD133+ cells (Torrente
et al., 2004). These cells display: (i) robust in vitro and in vivo
myogenic properties; (ii) skeletal muscle homing capability
upon intra-arterial delivery; (iii) ability to restore dystrophin
expression; and (iv) contribution to the satellite cell pool
(Torrente et al., 2004; Negroni et al., 2009). CD133+ cells can
be expanded and genetically manipulated in vitro, thus enabling
their application for autologous transplantations (Benchaouir
et al., 2007). Preclinical studies in dystrophic dogs demonstrated
that CD133+ cells can provide long-term muscle benefits in a
large animal model and provided important data regarding the
immune response toward the exon-skipped dystrophin produced
by the donor cells (Sitzia et al., 2016).
Mesenchymal Stromal Cells
Mesenchymal stromal cells (MSCs), also defined as mesenchymal
stem cells, were originally identified in the bone marrow stroma
and subsequently in multiple different tissues. These cells
display self-renewing potential and the ability to differentiate
into bone, cartilage, adipocyte and fibroblasts (Sacchetti et al.,
2007; Bianco et al., 2013). Within the bone marrow, MSCs are
located in a subendothelial position on the outer surface of
sinusoids, a characteristic type of blood vessels (Bianco et al.,
2013). In human, prospective isolation of perisinusal MSCs
was demonstrated using CD146, CD105, ALP, STRO-1 and
VCAM1 (Chan et al., 2009), in contrast to CD105, CD90, and
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VCAM1 used for their murine counterpart (Vieira et al., 2012).
As there are contradictory results regarding the myogenic
differentiation potential of MSCs (Gang et al., 2009; Vieira
et al., 2010, 2012), it has been proposed that MSCs exert their
function mainly through paracrine/secretory activity, supporting
the idea that they have immune-modulatory properties
(Ichim et al., 2010).
Pluripotent Stem Cell-Derived Myogenic
Progenitors
Given their ability to generate all of the cell types within
an organism, pluripotent stem cells (PSCs) are an attractive
potential source of myogenic progenitors for both basic and
translational studies (for a comprehensive review, please see
Magli and Perlingeiro, 2017). Derivation of myogenic cells from
PSC cultures can be achieved using transgene-, growth factor- or
teratoma-based differentiation systems (Magli et al., 2017).
Constitutive or inducible expression of the myogenic
transcription factors MyoD, Pax3 or Pax7 is sufficient for driving
specification of the myogenic lineage in both murine and human
PSCs (Darabi et al., 2008, 2012; Albini et al., 2013; Maffioletti
et al., 2015). Myogenic progenitors generated using this method
display robust in vitro differentiation, contribute to muscle
regeneration in vivo, and are able to replenish the satellite cell
pool. Transcriptomic analysis of PAX7-inducible human PSC-
derived myogenic progenitors revealed these cells are defined by
the expression of CD54 (ICAM1), Syndecan 2 and Integrin α9β1
(Magli et al., 2017). Although PSC-derived progenitors display
properties exhibited by embryonic cells, exposure to the in vivo
muscle environment is sufficient to induce a molecular switch to
a postnatal phenotype (Incitti et al., 2019).
Myogenic specification of PSCs can also be achieved
by sequential modulation of signaling pathways controlling
embryonic patterning and muscle development (Borchin et al.,
2013; Chal et al., 2015; Choi et al., 2016; Xi et al., 2017; Wu
et al., 2018). In general, these differentiation protocols involve
the specification of a paraxial mesoderm intermediate, which is
then directed toward the myogenic lineage. These cells can be
prospectively isolated using a subset of surface markers (ERBB3,
NGFR, CXCR4, MET, CD24, CD10) (Borchin et al., 2013; Hicks
et al., 2018; Wu et al., 2018), and express the transcription factor
Pax7 (Borchin et al., 2013; Chal et al., 2015; Hicks et al., 2018;
Wu et al., 2018). The combination of directed differentiation
and MYOD expression has also been applied to generate MABs
from human PSCs (Tedesco et al., 2012). Similar to their muscle-
derived counterparts, these cells display robust in vitro and in vivo
myogenic properties.
Recent studies have shown that teratomas represent potential
sources of muscle and other lineage-specific progenitors (Suzuki
et al., 2013; Chan et al., 2018). Myogenic cells were derived from
murine teratomas induced by injecting PSCs in immunodeficient
mice and purified using murine satellite cell markers (Chan
et al., 2018). While murine teratoma-derived myogenic cells
are endowed with myogenic regenerative potential, future
studies are needed in order to validate this finding in
human teratomas and to assess their safety for potential
clinical application.
In combination with gene delivery (Tedesco et al., 2012;
Filareto et al., 2013) or gene editing technologies (Young et al.,
2016), and clinically compatible purification strategies (Magli
et al., 2017), PSCs provide the opportunity to produce autologous
or allogeneic myogenic progenitors for regenerative medicine
applications. A critical aspect for the effective application
of PSC-derived cells is their safety (Andrews et al., 2017).
Since, the presence of undifferentiated cells may result in
tumor formation, and both PSC reprogramming and genomic
engineering may result in the acquisition of chromosomal
abnormalities. While these potential issues are relevant, ongoing
technological advances will likely produce novel solutions that
will enhance the safety of PSC-derived cells. These include
strategies aimed at generating myogenic progenitors (not
myocytes) through direct reprogramming from fibroblasts (Ito
et al., 2017; Bar-Nur et al., 2018; Sato et al., 2019), and inclusion of
suicide genes for elimination of potential donor-derived tumors
(Liang et al., 2018).
Novel Technologies That Could Improve
Cell Therapy of Muscle Disorders
An important aspect to take into consideration in regenerative
medicine is the potential immune response toward proteins
expressed by the transplanted progenitor cell population. This
becomes more relevant in the case of genetic disorders due
to mutations/lack of specific genes. Current efforts aimed at
minimizing this issue include the generation of cells capable
of evading immune surveillance. This can be achieved by
manipulating genes underlying antigen presentation (HLA I and
II), or by expressing genes that repress T cell stimulation (e.g.,
CTLA and PD-L1) or regulate immune function (e.g., CD47 and
CD200) (Lanza et al., 2019).
In addition to these various strategies aimed at generating
healthy muscle fibers, there have been attempts to intervene on
the muscle environment by reducing fibrosis (Cordova et al.,
2018). An interesting approach for targeting specifically fibrotic
tissue was documented in murine hearts using engineered T cells
recognizing proteins specifically expressed in cardiac fibroblasts
(Aghajanian et al., 2019). While there are no data regarding
the application of these cells in the context of skeletal muscle
disorders, it is possible that future therapeutic interventions in
dystrophic muscles will utilize a combination of strategies aimed
at both promoting muscle repair while decreasing fibrosis using
chimeric antigen receptor (CAR)-T cells.
CELL TRANSPLANTATION IN
DUCHENNE MUSCULAR DYSTROPHY
DMD (OMIM#310200) is a severe X-linked neuromuscular
disorder with childhood onset that causes progressive muscle
weakness and degeneration resulting in functional decline, loss
of ambulation and early death from cardiac or respiratory failure.
DMD is caused by mutations in the DMD gene, which encodes
for one of the largest human proteins called dystrophin that
links the actin cytoskeleton to the extracellular matrix through
the dystrophin-glycoprotein complex (DGC) thus regulating the
proper function of skeletal muscle fibers (Hoffman et al., 1987).
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The lack of dystrophin leads to progressive muscle
degeneration as the consequence of membrane instability,
defects in maintaining calcium homeostasis, neuronal nitric
oxide synthase (nNOS) activity and NO signaling. DMD is
characterized by continuous cycles of muscle degeneration and
regeneration, inflammation, fibrosis and oxidative stress, which
lead to progressive muscle weakening and loss of muscle fibers
(Carpenter and Karpati, 1979; Allen et al., 2015). The idea of
cell-based therapy has therefore been one of the logical attempts
to treat DMD and was pioneered in the 1990s using myoblast
transplantation, as previously described in this review. The
advent of stem cell research renewed the interest in cell-based
therapy for DMD in the 2000s. Here we will describe the
application of muscle specific stem/progenitor cells (MPSCs) and
induced pluripotent stem cells (IPSCs) for the treatment of DMD.
Myoblasts
Although the early myoblasts trials in DMD or BMD generally
resulted in limited or no clinical effect, the intramuscular
injection of myoblasts always resulted in localized tissue repair
at the site of injection (Skuk and Tremblay, 2014). Many years
of work aimed at improving protocols of transplantation (Zhu
et al., 2007; Gargioli et al., 2008; Gilbert et al., 2010; Morgan et al.,
2010; Liu et al., 2012) led to significant dystrophin expression
in rodents, non-human primates and patients (Skuk et al., 2004,
2006), although expression remained invariably confined to the
sites of injection. During the follow-up visits, which in some
cases were performed more than 20 years after the procedure,
no significant myoblast-related adverse effects were reported.
Observed complications were mostly due to immunosuppression
when this was used. This reinforced the idea that myoblast
and in particular autologous myoblast transplantation could be
developed as a therapeutic approach for muscular dystrophies,
especially for localized forms, where intra-muscular injection
may elicit a significant benefit. This will be described in relation
to Oculo-Pharyngeal Muscular Dystrophy (OPMD).
Mesoangioblasts (MABs)
MABs have been considered highly attractive for the treatment
of muscular dystrophies as they can be systemically delivered
and egress blood vessels to colonize the “inflamed” dystrophic
muscles. Several studies have shown safety and efficacy in
different animal models of muscular dystrophy, including DMD
(Sampaolesi et al., 2003, 2006; Díaz-Manera et al., 2010; Tedesco
et al., 2011; Domi et al., 2015). Preclinical results encouraged
a phase I/IIa clinical study in humans. Allogenic intra-arterial
HLA-matched donor cell transplantation in five DMD patients
under immunosuppression (8–12 years; 3 ambulant and 2 non-
ambulant; total infused dose 0.23 × 108/Kg to 0.97 × 108/Kg;
EudraCT 2011-000176-33) was performed (Cossu et al., 2015).
The study was relatively safe, as only one patient developed a
clinically mute thalamic stroke possibly due to the angiographic
procedures and/or intercurrent atrial fibrillation (1 event out
of 23 total infusions). Functional measures were transiently
stabilized in 2 out of 3 ambulant patients, muscle biopsy revealed
some donor-derived dystrophin in one of them, but general low
level of donor DNA was detected. Follow-up visits 5 years later
did not reveal any further side effects or abnormal findings in
these patients (Previtali, Torrente, Cossu, unpublished results).
Critical re-evaluation of results suggested that low efficacy might
have been due to the advanced age of the patients and consequent
fibrosis, steroid therapy (reducing MABs extravasation) and
insufficient number of infused cells. A new study involving
intramuscular injection of autologous lentiviral-modified MABs
to promote exon skipping of exon 51 is currently underway in
Manchester and will confirm the level of efficiency of MABs
integration and function in human skeletal muscle.
Bone Marrow Derived-Hematopoietic
Stem Cells (HSCs)
Although initial studies raised excitement regarding the
possibility to treat DMD using bone marrow transplantation
(Ferrari et al., 1998; Bittner et al., 1999), later reports
demonstrated that HSC transplantation in mdx mice contributed
to <1% of total muscle fibers, with no increase in dystrophin
expression (Ferrari et al., 2001). Negative results have also been
reported upon delivery of HSCs in dystrophic dogs (Dell’Agnola
et al., 2004), and in DMD patients (Gussoni et al., 2002; Kang
et al., 2010).
CD133+ Cells
These multipotent stem cells have been shown to ameliorate
dystrophic phenotype and dystrophin expression in mdx mice
(Torrente et al., 2004). These cells have also been validated
in the context of genetic correction by exon skipping strategy,
suggesting their utility in the autologous transplantation setting
(Benchaouir et al., 2008). More recent studies in GRMD dogs
confirmed positive results in transplanted animals (Sitzia et al.,
2016), while studies in humans suggest reduced regenerative
capacity when these cells are harvested from DMD patients
(Meng et al., 2018). Consistent with this, a clinical trial of
intramuscular transplantation of CD133+ showed no integration
of the donor cells in the muscle fibers (Torrente et al., 2007).
Mesenchymal Stromal Cells (MSCs)
MSCs are endowed with immune-evasive and anti-inflammatory
properties that could be useful for treating secondary processes
caused by the lack of dystrophin (Ichim et al., 2010). A number
of studies have investigated the role of MSCs in DMD mouse
models, either by intramuscular or systemic administration,
showing modest engraftment but no significant improvement of
muscle contractile force nor of dystrophin expression (De Bari
et al., 2003; Chan et al., 2007; Liu et al., 2007; Feng et al., 2008;
Shabbir et al., 2008; Gang et al., 2009).
Human adipose-derived stromal cells (hASCs), characterized
by the 12 cell surface proteins HLA-DR, HLA-ABC, CD13,
CD29, CD31, CD34, CD44, CD45, CD73, CD90, CD105, and
CD11, have also been reported to have some beneficial effects.
hASCs were systemically administered in the DMD mouse (mdx)
and dog (GRMD) models and were shown to be well-tolerated,
with good muscle engraftment and some human dystrophin
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expression (Rodriguez et al., 2005; Vieira et al., 2012; Pelatti
et al., 2016). Similarly, human pulp derived stromal cells showed
significant engraftment in GRMD dogs but modest dystrophin
expression after systemic administration (Kerkis et al., 2008),
whereas intramuscular injection of human microfragmented fat
into mdx mice exhibited anti-fibrotic and anti-inflammatory
properties with minimal force improvement (Bouglé et al., 2019).
More recently, adipose tissue-derived CD146+ cells, representing
a pericyte subpopulation with myogenic potential, also showed
some beneficial effects in double dystrophin-utrophin knock-
out mice by promoting survival, but only during the treatment
period, suggesting that these cells have only a short-term effect
(Gomes et al., 2018).
Wharton’s jelly (WJ)-derived MSCs (human umbilical cord)
showed significant anti-fibrotic and anti-necrotic activity when
injected into mdx mice possibly through metalloproteinase-1
release (Choi et al., 2020). Umbilical cord-MSCs have also been
tested in humans through the intravenous infusion of three
patients with BMD (apparently 1 × 107 cells). The authors
reported safety, anecdotal gait improvement only in the pediatric
patient and no changes in the pathology (Li et al., 2015).
Intra-arterial and intramuscular administration of allogenic
WJ-MSCs were subsequently investigated in nine DMD (8–
14 years; 4 ambulatory and 5 non ambulatory; 16 × 106 cells/kg)
patients (NCT02484560). Again, the procedure was reported safe,
promoted improvement in pulmonary tests, some dystrophin
expression and CK reduction, but no improvement in motor
outcomes (Dai et al., 2018).
Finally, recent intramuscular injection of allogenic HLA-
matched bone marrow-MSCs and skeletal muscle-derived PSCs
has been performed in three DMD patients (11, 22, and 12
years; 700–860 × 106 cells in 9–18 cm2), with short-time
immunosuppression (Klimczak et al., 2020). Pathology and
motor functions did not change, reduction in CK levels is
questionable while some anti-inflammatory effects and minimal
dystrophin expression is reported.
Pluripotent Stem Cell-Derived Myogenic
Progenitors
Intramuscular transplantation of both mouse and human IPSC-
derived myoblasts into mdx mice showed contribution to muscle
formation and dystrophin expression (Mizuno et al., 2010;
Darabi et al., 2012), even in the absence of a pre-treatment
damage due to cardiotoxin injection (Zhao et al., 2020). Similar
findings have been achieved with direct reprogramming of IPSCs
into myogenic progenitors (Bar-Nur et al., 2018), even when
obtained with small molecules and thus avoiding problems
related to gene infection (He et al., 2020). Subsequent studies
showed that myogenic progenitors derived from genetically
corrected dystrophic PSCs can promote muscle regeneration
when administered to mdx mice (Filareto et al., 2013; Young et al.,
2016; Hicks et al., 2018). Similarly, genetically corrected PSCs
can be differentiated into MABs, which are endowed with muscle
homing potential upon systemic delivery (Tedesco et al., 2012).
Further studies are necessary to assess if these cells can be used in
human clinical practice due to possible risk of tumor formation.
Strategies aimed at promoting the bed-to-bedside transition of
PSC-derived myogenic progenitors include the identification of
surface markers enabling purification and successful in vivo
engraftment in mdx mice (Magli et al., 2017).
OCULO-PHARYNGEAL MUSCULAR
DYSTROPHY
As mentioned above, myoblasts may not be the ideal candidate
to treat muscle diseases which affect the majority of the body
musculature, such as DMD, but they are the ideal candidate for
treatment of muscle diseases affecting selectively small muscles
such is the case in OPMD. In fact, while cell therapy protocols
usually involve transplantation of gene-corrected autologous cells
or a combination of heterologous cells and immune suppression,
some muscular dystrophies with only a few affected muscles,
such as OPMD, can benefit from autologous transplantation of
autologous, non-modified cells from a non-affected muscle.
OPMD is an autosomal dominant genetic disease
characterized by a late onset. The mutation that causes
OPMD is an abnormal trinucleotide repeat expansion in the
PABPN1 gene, which affects primarily a small group of specific
muscles (eyelid and pharyngeal), leading to ptosis and dysphagia
(Banerjee et al., 2013).
When myoblasts were isolated from the unaffected muscles
of OPMD patients, they were shown to have the ability to
proliferate and differentiate in a manner identical to cells
isolated from normal control muscle (Périe et al., 2006). This
suggested that the autologous transplantation of myoblasts
isolated from the unaffected muscles of OPMD patients and
transplanted into the affected pharyngeal muscles could be
a possible therapy to restore muscle function and improve
swallowing and quality of life. Based on these results a phase I/IIa
clinical study (ClinicalTrials.gov, NCT00773227) was carried out
using autologous myoblasts isolated from clinically non-affected
muscles, expanded in vitro in GMP conditions. A median of 178
million myoblasts were injected into 12–20 different sites in the
upper pharyngeal muscles of 12 patients. Improvement in the
quality of life was observed in all 12 patients. The results of the
trial demonstrated safety and good tolerance of the procedure
with no adverse side effects. A cell dose dependent functional
improvement in swallowing was even observed in this safety
study. This trial supports the hypothesis that autologous myoblast
transplantation into the pharyngeal muscles of OPMD patients is
a safe and efficient therapeutical procedure to alleviate dysphagia
(Périé et al., 2014).
OTHER MUSCULAR DYSTROPHIES
Until now, DMD and OPMD are the only two forms of
muscular dystrophy for which cell-based clinical trials have been
performed. In OPMD, muscle stem cells from unaffected muscle
were transplanted into diseased pharyngeal muscle and indeed
improved swallowing. However, OPMD is a localized disease.
Limb Girdle MDs would not profit from an autologous setting in
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which a population of mutated muscle stem cells is transplanted
from one muscle to another. The possibility to repair mutations
in muscle stem cells has become a realistic perspective due to the
introduction of the CRISPR/Cas9 system into clinical medicine.
Indeed, it can be shown that primary human muscle stem cells
can be genetically corrected with almost 100% efficiency (Escobar
et al., 2021). An autologous transplant of corrected muscle stem
cells has developed into a realistic perspective. With this, all
the monogenic recessive muscular dystrophies are in principle
amenable to cell transplantation in patients, once the problems
of delivery to many different muscles and of low engraftment
will have been solved. Indeed, also dominant forms would
be treatable, but the approach would require silencing of the
mutated, dominant allele while guaranteeing expression of the wt
allele at sufficient levels to avoid haploinsufficiency.
Congenital muscular dystrophies are severe, early onset,
rapidly lethal diseases. They represent a dramatic unmet clinical
need and, ethically, would be compatible with a more aggressive
therapeutic approach (e.g., chemotherapy to kill diving myogenic
progenitors and thus enhancing engraftment of genetically
corrected cells). In these cases, there is no time to wait for future
alternative strategies. It should be noted though that gene therapy
for myotubular myopathy resulted in the death of two patients
following AAV administration (Wilson and Flotte, 2020).
Pre-clinical evidence of efficacy in mouse models has
accumulated over the last 20 years (Vilquin et al., 1999; Leriche-
Guérin et al., 2002; Sampaolesi et al., 2003; Tedesco et al., 2012;
Meregalli et al., 2013; Domi et al., 2015; Frattini et al., 2017; Azzag
et al., 2020). Nonetheless, it should be remembered that results
obtained in mice are usually superior to what later observed
when the same approach is tested in large animal models (almost
exclusively the dog in the case of MD) and in patients. It this thus
probable that these other muscular dystrophies will have to wait
the successful completion of work on DMD.
MITOCHONDRIAL MYOPATHIES
Skeletal muscles are high energy requiring tissues and this energy
is predominantly produced by the mitochondrial oxidative
phosphorylation (OXPHOS) system. Impaired OXPHOS
functioning can result in a mitochondrial myopathy (MM),
which is one of the most common manifestations of adult-
onset mitochondrial disorders. Mitochondrial disorders are
both clinical and genetically heterogeneous and often involve
multiple organ systems. MM patients commonly present chronic
progressive external ophthalmoplegia (CPEO), either as an
isolated symptom or in combination with proximal myopathy,
exercise-induced muscle pain and/or fatigue (Greaves et al.,
2010; Ahmed et al., 2018). In contrast to muscular dystrophies,
MM is generally slowly progressive and is not associated with
severe muscle wasting (Shieh, 2013; de Barcelos et al., 2019). MM
has a large impact on the patient’s quality of life and no effective
treatment is currently available. Dietary supplements, aimed at
improving mitochondrial function, are often prescribed, but
the long-term efficacy has not been demonstrated (Pfeffer et al.,
2012; Ahmed et al., 2018; de Barcelos et al., 2019).
The mitochondrial OXPHOS system is under control of both
the nuclear and the mitochondrial genome. Nuclear encoded
genes include subunits and assembly factors of the OXPHOS
system, as well as proteins for mtDNA maintenance, and large
number of mutations have been identified in >250 of the
∼1,500 nuclear encoded genes linked to OXPHOS functioning
(Lightowlers et al., 2015; Alston et al., 2017). In addition,
disease-causing point-mutations and large-scale deletions have
been identified in the 16,569 bp circular mitochondrial DNA
(mtDNA). Since each cell has multiple mtDNA copies, a
mtDNA mutation can be present in all mtDNA copies, called
homoplasmy, or there can be a mixture of both wild-type and
mutated mtDNA copies in a cell, which is called heteroplasmy.
In contrast to nDNA mutations, in which the amount of wild-
type protein is either reduced by 50% or is completely absent,
the effect of a heteroplasmic mtDNA mutation on mitochondrial
functioning depends on the percentage of mutated copies present,
ranging between 0 and 100%, and on the tissue specific threshold.
In skeletal muscle of 40 MM patients with either a mtDNA
point-mutation or a large-scale deletion, a negative correlation
has been identified between the mtDNA mutation load and
OXPHOS functioning (Taivassalo et al., 2003), and a positive
relation has been shown between the skeletal muscle mtDNA
mutation load and exercise intolerance in 51 m.3242A>G
mutation carriers (Jeppesen et al., 2006). Increasing the total
mtDNA copy number demonstrated to alleviate symptoms
in mice with a pathogenic heteroplasmic mtDNA mutation
encoding tRNA alanine (Filograna et al., 2019), suggesting that
either a partial reduction in mtDNA mutation load or an
increase in the number of mtDNA copies per cell would facilitate
normal OXPHOS functioning and could potentially result in
clinical improvement. In line with this, increasing mitochondrial
biogenesis by endurance exercise training has been successfully
applied in mtDNA mutation carriers (Taivassalo et al., 2001;
Jeppesen et al., 2009), but is often not feasible because of exercise-
induced lactate production or due to other clinical symptoms.
Also, preferential replication of the mutated mtDNA can occur,
which will worsen OXPHOS function (Taivassalo et al., 2001).
In addition to endurance exercise training, a 12-week resistance-
type exercise training program, aimed at inducing myogenesis,
resulted in increased muscle strength, muscle regeneration,
improved oxidative capacity, and increased number of NCAM+
satellite cells in carriers of a sporadic large-scale mtDNA deletion
(Murphy et al., 2008). Given the fact that satellite cells of sporadic
large-scale mtDNA deletion carriers have been demonstrated to
contain either a low or absent level of deleted mtDNA (Moraes
et al., 1989; Spendiff et al., 2013), and the observation that
resistance-type exercise resulted in a small yet non-significant
reduction in heteroplasmy level (Murphy et al., 2008), suggests
that satellite cell activation is a valid therapeutic approach in
order to induce muscle regeneration and improve mitochondrial
function. Moreover, mtDNA mutation free satellite cells have
been identified in carriers of a sporadic mtDNA point-mutation
(Fu et al., 1996; Shoubridge et al., 1997; Taivassalo et al., 1999),
and Shoubridge et al. (1997) demonstrated by repeating biopsies
at the damaged muscle site, that the regenerating fibers contained
solely wild-type mtDNA copies, suggesting the incorporation
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of satellite cells can improve muscle function in carriers of a
sporadic mtDNA deletion. Since most mtDNA mutation carriers
display systemic muscle weakness, satellite cells’ requirement for
intra-muscular injection strongly limits their application due to
requirement of the large amounts of injections (Morgan et al.,
1993). Alternatively, MABs have the ability to be systemically
delivered via intra-arterially transplantation. Transplantation of
donor MABs has been shown to result in functional improvement
of multiple muscular dystrophy animal models (Sampaolesi et al.,
2003, 2006) and was found to be relatively safe in children
with DMD (Cossu et al., 2015). The identification of mutation-
free satellite cells in mtDNA mutation carriers, prompts the
question if MABs of these patients also display low or absent
mutation load. A study of 19 patients with maternally inherited
mtDNA point mutations and six carriers of a sporadic large-
scale mtDNA deletion, demonstrated that all of the large-scale
mtDNA deletion carriers displayed wild-type MABs and nearly
half of the point mutation carriers display a mtDNA mutation
load below <10%. All mtDNA-mutation free MABs displayed
normal mitochondrial function, demonstrating their suitability
for therapeutic application (van Tienen et al., 2019). Currently,
a phase I clinical study (EudraCT 2016-001258-16) is ongoing
in which autologous mtDNA-mutation free MABs are intra-
arterially delivered in m.3243A > G mutation carriers, which
will provide insights into the safety and potential of autologous
MABs cell therapy for MM. The application of autologous cell
therapy would be beneficial over allogeneic stem cell therapy, as
it does not require the use of immunosuppressive agents. This
would be beneficial for the patient, as an immunosuppressive
regimen makes them more vulnerable to infections (Porrett
et al., 2014; Halter et al., 2015). Moreover, for intra-arterial
MABs transplantation, inflammation is required for skeletal
muscle engraftment, which might be impaired by the use of
immunosuppressive agents (Cossu et al., 2015). It should be
noted that MM patients generally do not display significant
muscle inflammation and inflammation needs to be induced
prior to intra-arterial delivery of MABs. This can be induced by
a bout of maximal eccentric exercise that results in upregulation
of inflammation markers, such as SDF1α and TNFα, which are
associated with increased migration of MABs (Galvez et al., 2006;
Valero et al., 2012; Nederveen et al., 2018).
In contrast to mtDNA mutation carriers, MM patients with
a nDNA mutation will always require genetic correction in
order to obtain nDNA-mutation free autologous stem cells for
therapy. In recent years, CRISPR-Cas9 based genetic correction
strategies are quickly emerging for numerous diseases (Sharma
et al., 2021). For correction of MM-causing nDNA mutations,
strategies will likely need to be tailored for each MM patient
individually, as most patients present a unique mutation.
This will be challenging, as it requires the development of
a modular procedure for stem cell isolation and expansion,
and inclusion of a tailored correction procedure. In line
with this, for mtDNA-mutation carriers that do not display
mtDNA-mutation free stem cells, lowering of the mtDNA
mutation load needs to be achieved. To this end, degradation
of the mutant mtDNA using mitochondrial-targeted TALEN
or CRISPR/Cas9 (Bacman et al., 2013; Jo et al., 2015), and
replication inhibition of the mutant mtDNA using peptide
nucleic acids (PNAs) have been explored (Chinnery et al.,
1999). However, given the multiple copies of mtDNA in all
mitochondria per cell, all strategies require effective delivery
of the components into the majority of the mitochondria in
each cell. To this end, liposome-based carrier systems are being
developed, such as the MITO-porter and nanosome systems
(Yamada et al., 2008; Bae et al., 2017), but require further research
before they can be applied to correct stem cells for clinical
application.
In conclusion, (autologous) myogenic stem cell therapy for
MM has not been applied yet, but the road to clinical application
appears to be most straightforward for mtDNA mutation carriers,
as mtDNA-mutation free stem cells can be directly obtained
from a number of these patients. For MM patients with nDNA
mutations and mtDNA mutation carriers that do not display
mtDNA-mutation free myogenic stem cells, further research will
be required in order to safely and effectively perform ex vivo
genetic correction in a GMP-compliant procedure.
INCLUSION BODY MYOSITIS
The idiopathic inflammatory myopathies (IIMs) are a group
of acquired autoimmune diseases where skeletal muscle
inflammation is the predominant clinical feature (Oldroyd
et al., 2017). Proximal limb weakness, myalgia, and fatigue
are core symptoms, often with co-existing extra-muscular
involvement, such as interstitial lung disease. The IIMs are rare
with a prevalence of 2.4–33.8 per 100,000 (Meyer et al., 2015).
Initially segregated into only polymyositis and dermatomyositis,
increased heterogeneity within the IIM spectrum is evident,
with immune mediated necrotizing myopathy, inclusion body
myositis (IBM), anti-synthetase syndrome and overlap syndrome
recognized subtypes. Each IIM subtype has well-defined clinical
characteristics, histopathological findings on muscle biopsy,
and serum autoantibody associations (Mariampillai et al., 2018;
Betteridge et al., 2019). Most of IIMs respond to steroids and/or
immune suppression and for this reason they are not of primary
relevance for cell transplantation (Oldroyd et al., 2017).
IBM is the most common acquired myopathy in those
aged >50 years. Compared to the other IIMs, IBM differs
in terms of its pathological phenotype, where mitochondrial
dysfunction and protein aggregation (e.g., amyloid, p62, TDP-
43) are prominent clinical features, where focal involvement of
forearm flexors and knee extensors is typical, as well as lack
of response to conventional immunosuppression (Greenberg,
2019). There are no effective disease modifying treatments for
IBM and as such, patients suffer from relentless accumulation
of disability, including grip weakness, knee instability, falls, and
dysphagia (Rose et al., 2015). This deterioration is accompanied
by progressive, focally severe, atrophy and fatty replacement
of skeletal muscle. Overall, IBM behaves clinically more like
a late-onset muscular dystrophy rather than an inflammatory
myopathy. Whilst such tissue damage can be seen in other IIM
subtypes, it can usually be avoided with early and appropriately
aggressive immunosuppressive therapy.
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The strikingly focal muscle involvement seen in IBM means
that of the IIMs is the most amenable to a cell therapy approach
for treatment, rescuing tissue by targeted delivery of cells to
the affected areas. For example, long finger flexor muscles could
be targeted directly using an intramuscular injection technique
or affected muscle groups could be targeted using a segmental
intra-arterial injection of myogenic progenitors with potential
for vessel wall migration, such as MABs (Sampaolesi et al.,
2003). With similarity to targeted botulinum toxin injections
for treating dysphagia, targeting specific diseased muscles could
ameliorate important aspects of the disease (e.g., grip weakness),
without requirement for systemic treatment administration and
associated adverse effects (Schrey et al., 2017).
Despite the potential for myogenic cell therapy to offer a new
therapeutic option for IIM, there has been very little research
or progress in this area. One study has described the apparent
beneficial effects of transplantation of adipose derived stem cells
into a mouse model of IBM, but this has been published in
abstract form only (Fabry et al., 2017). It should also be noted
that whilst transplantation of such cells may have an anti-
inflammatory effect, they do not have myogenic potential.
Regarding intra-arterial cell delivery, the inflammatory milieu
in IBM muscle is expected to facilitate movement of MABs across
the vessel wall if an intra-arterial delivery strategy is developed
(Sampaolesi et al., 2003). As compared to SCs, MABs have better
survival and migration capacity, and express adhesion molecules
which enable them to traverse the vascular endothelium.
Furthermore, MABs potently suppress human CD4 and CD8
T-cell proliferation and effector function in vitro (English et al.,
2013). This may have relevance in terms of the populations of
highly differentiated CD28null T-cells found in IBM muscle,
known to be resistant to conventional immunosuppression and
likely to be a key factor explain the treatment refractory nature of
IBM (Greenberg et al., 2016; Pandya et al., 2016).
SPHINCTER INCONTINENCE
Sphincter muscles are other defined, functionally highly relevant
muscles, well-suited for autologous transplantation.
Anal sphincter muscle anomalies result in fecal incontinence
(FI) with devastating physical consequences and psychosocial
dysfunction. FI causes major embarrassment and may lead
to social exclusion. Population surveys suggest FI prevalence
ranging from 2 to 17% (Perry et al., 2002; Kuehn, 2006;
Siproudhis et al., 2006; Parés et al., 2015). However, the majority
of affected persons do not consult a physician (Lam et al.,
1999). In the French population for instance, 1 million people
are concerned by FI, 350,000 of whom suffer from severe
incontinence (more than once a week). This disease not only
concerns the elderly (30% of people over 70 years living in
long-term care institutions) but also significantly affects young
women following delivery (Denis et al., 1992). A high frequency
of postpartum FI has been reported following vaginal birth
(4–38%) (LaCross et al., 2015). This frequency renders the
disease a public health concern and a personal, social and
economic handicap. FI still is confronted significant therapeutic
management difficulties today despite the various existing
treatments: drugs to regulate intestinal transit, anoperineal
rehabilitation with biofeedback, surgical treatment by various
techniques such as: sphincterorrhaphy or submucosal injections,
sacral nerve stimulation and colostomy which is the last
possible alternative.
Cell therapy by injection of autologous myoblasts would have
many advantages over most alternative methods. A first pilot
study of myoblast transplantation for the treatment of FI was
carried out by an Austrian team who demonstrated the tolerance
of the product (Frudinger et al., 2010). Rouen University Hospital
then performed a randomized double-blind placebo-controlled
phase II clinical trial (ClinicalTrials.gov, NCT01523522, MIAS-
01, 24/24 patients included, autologous myoblasts produced by
Rouen UH cell therapy facility) (Boyer et al., 2018). Results at 12
months post treatment demonstrated that injection of autologous
myoblasts (AM) into the striated sphincter of patients with FI
provides a clinical benefit, with a much higher benefit at 12
months in the treated arm than in the placebo arm (58 vs.
8%, P = 0.03). A positive response to autologous myoblast cell
therapy was defined as a reduction of 30% in the Cleveland
Clinic Incontinence CCI. Similar results were also found after the
injection of frozen AM in patients initially in the placebo group,
with a response rate of 60% (6/10) at 12 months (Boyer et al.,
2018). It should be noted that at 6 months, transient not persistent
placebo effect was observed.
In other strategy, Thin et al. (2013) reported similar results
with sacral nerve stimulation (SNS), with response rates between
58 and 63%. Response was defined on the basis of a standardized
stool diary with a reduction of more than 50% of FI episodes
over a period of 3 weeks at 12 months post treatment. However,
regular replacement of the pacemaker is required (approximately
every 5 years) and in the long run it remains expensive.
Together these results strongly support the therapeutic efficacy
and justify conducting a phase III multicenter trial: a multicenter
randomized phase III clinical trial (MIAS-02, Myoblasts for
Insufficient Anal Sphincter-02). The purpose of this study is to
compare two surgical treatments of severe FI. The hypothesis of
this "non-inferiority" trial is that injection of myoblast is clinically
as effective as SNS in managing FI and could be proposed as an
alternative therapy for these patients. The trial is currently being
planned, with some (from PHRC, French National Research
Program 2017) but non all needed funds yet secured.
In addition to FI, sphincter deficiencies comprise the urinary
incontinence (UI) syndrome. UI is a widespread disease, affecting
more than 200 million people worldwide (Norton and Brubaker,
2006). However, this subsumes different clinical forms and
pathophysiology.
Stress urinary incontinence is the most common form of
UI; the etiology involves a weakness of the urethral sphincter
muscle. Animal models do not accurately mimic the distinct
human conditions. Preclinical efficacy studies involving artificial
damage of the rat urethral sphincter and consecutive autologous
myoblast injection into the defect site indicate significant
therapeutic potential (Chermansky et al., 2004). In line, muscle-
derived cells have been investigated in numerous studies to
regenerate the sphincter and improve continence function in
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stress UI (Aragón et al., 2018). The characterization of the cell
products used as well as the mode of application, dosing and
outcome measures differ. Yet, the feasibility of cell production,
administration as well as safety are evident. While first efficacy
data have appeared promising, the high importance of the
rigorous, high-quality study design (control arm, blinding,
stringent outcome measures) emerges. Interim analysis of a
recent double-blinded, randomized, placebo-controlled design
revealed a high placebo response rate evaluating the safety and
efficacy of autologous muscle derived cells in stress UI (Jankowski
et al., 2018). Post-hoc analyses suggested that the efficacy endpoint
had not been defined restrictively enough.
Due to the heterogeneity of the UI patient population,
trials focusing on defined disease etiologies and thus clinically
homogenous patient subgroups are highly relevant to consider
for the evaluation of the therapeutic potential of myoblasts.
The exstrophy-epispadias complex (EEC) is an orphan, prenatal
developmental disorder of the lower abdominal wall, bladder,
and genitalia. EEC results from mechanical disruption or
enlargement of the cloacal membrane (Ebert et al., 2009).
Reconstructive surgery is the main treatment with relevant
functional and cosmetic outcome. However, lifelong urinary
incontinence remains a major medical problem. The incomplete
development of the urethral sphincter leads to a small,
circumscribed muscular defect (few mm). At the defect site
muscle is replaced by vascularized and innervated connective
tissue; the urothelium is intact (Canon et al., 2008). Current
interventions primarily aim to establish social continence (def:
dry interval of more than 3 h during the day; Chan et al.,
2001). Bladder neck reconstruction (BNR) is a major surgery
with the goal of forming a passive increase in bladder outlet
resistance through irreversible anatomical reconstruction in the
bladder neck region (Mollard and Mure, 2001). BNR results
in social continence in half of the children (Shoukry et al.,
2009). Seventy-five percentage of patients are lifelong dependent
on catheterization or other non-physiologic urinary drainage
(Maruf et al., 2020). Complications include recurrent infections,
urinary stones, dilatation of the upper urinary tract, urinary
retention, renal impairment, metabolic complications, increased
risk of cancer, revision surgery, hospitalization, as well as wide-
ranging limitations in daily life and severe psychological distress
(Mouriquand et al., 2003; Surer et al., 2003; Ebert et al., 2020).
Treatments to establish physiologic continence are required.
In a single-arm study autologous muscle cells were injected
into the urethral sphincter defect of eight children with EEC
(Kajbafzadeh et al., 2008). All boys included in the trial
showed improvement of continence function after 6 months
as measured by urodynamics (increased bladder capacity, leak
point pressure, maximum urinary flow). In the 4-year follow-
up, safety-related complications were not reported. Quality of life
improved significantly. Five of the seven boys were reported to
be physiologically continent, two socially continent (Elmi et al.,
2011). These data reinforce the need for subsequent controlled
studies involving international cooperation in this rare disease (in
preparation: NCT04729582).
To conclude, the early implementation of the randomized and
placebo-controlled clinical trial design is critical to investigate
the clinical efficacy of autologous myoblast transplantation,




Skeletal muscle has a remarkable capacity to regenerate upon
injury; however, when muscle repair fails scar tissue replaces
the damaged area with resultant functional impairment as
seen in myopathies, muscle denervation, muscle ablation upon
surgery but also in cachexia and sarcopenia. The rapid and
focal loss of skeletal muscle with resultant functional impairment
has been defined as VML (Minetto et al., 2021), while the
progressive loss of muscle mass and function observed in elderly
people or in patients affected by cancer or chronic diseases is
referred to sarcopenia and cachexia, respectively (Cassano et al.,
2009; Berardi et al., 2014). The current procedure for severe
VML injuries involves muscle flap transplantation, generally
autologous muscle flaps containing proper vasculature. Similar to
muscle flaps, clinically relevant skeletal muscle tissue engineering
constructs are developed in preclinical studies and they include
vascular networks to improve cell survival deeper than a few
hundred micrometers within the tissue, which is the limit of
passive diffusion. Alternative strategies include the use of fibrin
hydrogels in combination with muscle-derived stem cells or
iPSC-derived myogenic progenitors (Matthias et al., 2018; Wu
et al., 2021), which are associated with an improvement in
muscle contractility in a murine VML model. In sarcopenic
and cachectic conditions, dysregulated hormones, cytokines and
mechanic loading facilitate protein degradation while impairing
protein synthesis and affecting muscle fiber size and contractile
functions. In particular, tumor necrotic factor alpha (TNFα)
or interleukin 1 (IL-1) trigger their receptors TNFR1 and IL-
1R, respectively and promote the translocation of NF-κB into
the nucleus and the induction of gene transcription factors,
including MuRF1 with the consequent muscle atrophy (Cai et al.,
2004). Thus, it is not surprising that the majority of translational
research studies explored pharmacological protocols to invert
the balance between protein synthesis and degradation. Indeed,
anti-inflammatory drugs to target pro-inflammatory cytokines
elevated in plasma of patients with muscle wasting conditions
have been extensively used albeit with mixed success (Furrer and
Handschin, 2019).
More recently, independent groups have reported that muscle
progenitor cells are impaired in muscle wasting conditions
and in particular they accumulate in atrophic muscles without
proceeding further toward myogenic differentiation. In this
pathological muscle condition, the activation of NF-κB in
myogenic progenitors maintains persistent expression of PAX7
that prevents the expression of late transcription factors necessary
for myogenic maturation (He et al., 2013; Brzeszczyńska et al.,
2016). Moreover, cell autonomous intrinsic changes due to aging
affect the myogenic differentiation potential of human muscle
progenitors and cannot be reversed when they are exposed
to a young environment in xenotransplantation experiments
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(Rotini et al., 2018). BMPs and myostatin pathways are also
implicated in the age-related muscle degeneration (Scimeca
et al., 2017) and in general BMP-SMAD signaling blockade
improves myogenic differentiation of muscle progenitors (Ono
et al., 2011; Costamagna et al., 2016). Similar to satellite
cells, MABs accumulated in cachectic muscles and when
they are isolated from the atrophic muscles are still able
to directly contribute to myogenesis in vivo. In C26 colon
carcinoma-bearing mice the function of muscle stem cells can
be preserved by the administration of interleukin 4 (IL-4)
that acts as anabolic agent to skeletal muscle, reducing also
systemic inflammation and increasing muscle protein synthesis
(Costamagna et al., 2020). Commonly, IL-4 as well as IL-
1 are considered cytokines promoting oncogenesis; however,
IL-4 induces muscle regeneration and function. In addition,
the presence of large necrotic regions enriched with type II
macrophages and CD8+ lymphocytes in IL4-treated tumors
suggests a relevant cytotoxic effect. Thus, the role of the IL-
4 in cancer associated cachexia is currently ill defined and
may provide the bases for the development of new therapeutic
strategies combatting both tumor and cachexia.
Thus, it seems that muscle stem cell populations are still
present in muscle wasting, however, they are unable to counteract
the pathological condition, and some of them cannot complete
the differentiation process despite maintaining their intrinsic
myogenic potential. Although lineage tracing studies show that
satellite cells fuse into myofibers in sedentary mice throughout
the lifespan (Keefe et al., 2015), loss of function experiments
provide evidence that lifelong genetic depletion of satellite cells
in transgenic mice did not increase the severity of sarcopenia
(Fry et al., 2015). In this view, genetic and/or pharmacological
interventions to interfere with myogenic stem cell activation,
autophagy or muscle protein turnover may offer preferential
treatments for cachectic and sarcopenic muscles. In addition, an
appealing solution for severe VML injuries is the use of stem cells
combined with bio-scaffolds, fibrin gel among others, to promote
muscular and vascular regeneration and limit fibrosis and scar
tissue formation.
CONCLUSION
By summarizing all the information described above, we may
conclude:
1. Muscle diseases are diverse: hereditary or acquired,
generalized or local. Pathological muscle weakness has
enormous implications for the affected individual and for
society as a whole, considering that certain diseases are
very common. Major therapeutic breakthroughs have not
reached clinical routine.
2. A complex and diversified methodological approach
still needs to be optimized for the various myogenic
progenitors to allow long term expansion in vitro with
maintenance of self-renewal and differentiation potency.
3. Promising preclinical studies led to the early translation
into clinical application and have demasked the related
challenges and bottlenecks. Today, we can benefit from
the insights of this pioneering work. This urges for further
developments.
4. A variety of different approaches of cellular therapies
are under development. In this review, we outline
core strengths and limitations for different cell types.
First promising clinical results not only have proved
safety but also efficacy in localized muscle impairment
(Kajbafzadeh et al., 2008; Périé et al., 2014; Boyer
et al., 2018), point toward the indispensability of the
precise identification and matching of biological and
pharmacological properties of the used cell drug to the
underlying disease to be treated. Emerging evidence will
identify optimal therapeutic strategies, likely involving
combinatorial therapy.
5. Cell therapies for muscle diseases need to be implemented
and adequately funded. These gene and cell therapeutics
are classified as Advanced Therapy Medicinal Products
(ATMPs), a distinct class of drugs that was first legally
defined in 2007/(REGULATION (EC) No 1394/2007
OF THE EUROPEAN PARLIAMENT AND OF THE
COUNCIL of 13 November 2007 on advanced therapy
medicinal products and amending Directive 2001/83/EC
and Regulation (EC) No 726/2004). Well-established
principles in classical drug development are transferable
to these ATMPs only to a limited extent, due to the
nature of cells and their mode of action. Recently, the
EMA has invested significant effort in the standardization
of distinct ATMP-related sub-aspects (European
Medicines Agency, 2019) EMA/CAT/499821/2019.
A muscle-specific addendum is pending. The pooling of
expertise of basic scientists and clinicians from multiple
disciplines, regulators, and drug manufacturers, offers the
opportunity of facilitating the herewith described efforts
and comparability. This will require the harmonization
of the preclinical characterization of the investigational
medicinal product. As an example, the standardization
will mutually accelerate dose finding strategies.
6. Analysis of ATMP related clinical trials and potential
later marketability highlight the importance of the
early implementation of a randomized and controlled
clinical trial design to investigate the clinical efficacy
(Elsallab et al., 2020). In rare diseases, such as muscular
dystrophies, highly innovative study designs must be
implemented (Chow and Huang, 2020). A mutli-center
collaboration may advance outcome measurements
impacting patients’ everyday life. A lack of larger scale
trials ultimately delays clinical readiness of innovation.
7. The ATMP status is associated with high upfront costs in
developing the pharmaceutical manufacturing process
and to produce the cell product for clinical trials.
The innovative power in academic institutions for the
emergence of these new therapies in predominantly
rare disease, necessitates public funding of such
studies as a vehicle for success and for clinical
translation of these valid therapeutic options for today’s
unmet medical needs.
8. We encourage the scientific, pharmaceutical and
regulatory communities to join forces and work together
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to produce mutual guidelines for preclinical core
requirements and on innovative strategies for clinical
trial conduction in advancing cell therapies for muscle
diseases and to strengthen the efforts for effective
treatments.
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